Latent Class Analysis Reveals, in patient profiles, COVID-19-related better prognosis by calcifediol treatment than glucocorticoids
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Calcifediol treatment significantly improves prognosis for hospitalized COVID-19 pneumonia patients, reducing intensive care unit admissions. This benefit is most pronounced when calcifediol is administered without glucocorticoids.
Area Of Science
- Infectious Diseases
- Pulmonology
- Endocrinology
Background
- Repurposed drugs like calcifediol and glucocorticoids are being investigated for COVID-19 treatment.
- These agents may potentially reduce disease severity, intensive care unit (ICU) admission, and mortality.
Purpose Of The Study
- To identify patient profiles in COVID-19 pneumonia using latent class clustering.
- To assess the clinical and prognostic relevance of these patient profiles.
- To investigate differential responses to calcifediol treatment.
Main Methods
- Retrospective observational cohort study at Reina Sofia University Hospital, Córdoba, Spain.
- Included 707 patients aged 18-90 with confirmed SARS-CoV-2 pneumonia and CURB-65 score >1.
- Latent class analysis was employed to identify patient clusters, with outcomes defined as poor (death/ICU admission) or good prognosis.
Main Results
- Three distinct patient clusters were identified based on treatment and prognosis.
- Patients treated with calcifediol alone (Class 3) showed significantly better prognosis compared to those receiving glucocorticoids alone or no treatment.
- Class 3, with 60% receiving calcifediol, demonstrated a significantly better prognosis (OR: 15.2 vs. glucocorticoids alone, OR: 7.38 vs. no treatment).
Conclusions
- Real-world evidence indicates calcifediol treatment significantly reduces ICU admissions and improves prognosis in COVID-19 pneumonia patients.
- The most significant benefit of calcifediol was observed in patients receiving it without concomitant glucocorticoid therapy.
- Calcifediol represents a promising therapeutic option for hospitalized COVID-19 pneumonia.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Primary Step: The most critical intervention for all COPD patients who smoke.
Benefits: Slows disease...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...